human
plasma
sourc
wide
varieti
therapeut
protein
yet
also
potenti
sourc
viral
contamin
recent
outbreak
emerg
viral
pathogen
west
nile
viru
use
live
vaccinia
viru
vaccin
prompt
reassess
viral
safeti
plasmaderiv
product
purpos
studi
evalu
efficaci
current
viral
inactiv
method
west
nile
vaccinia
virus
reassess
use
model
virus
predict
inactiv
similar
viral
pathogen
virusspik
product
intermedi
process
use
downscal
represent
variou
manufactur
procedur
viru
infect
measur
process
determin
viru
inactiv
result
demonstr
effect
inactiv
west
nile
viru
vaccinia
viru
model
viru
bovin
viral
diarrhoea
viru
pasteur
solvent
deterg
treatment
capryl
treatment
capryl
provid
rapid
effect
inactiv
west
nile
viru
vaccinia
viru
duck
hepat
b
viru
sindbi
viru
inactiv
west
nile
viru
similar
bovin
viral
diarrhoea
viru
conclus
studi
demonstr
procedur
use
inactiv
envelop
virus
manufactur
process
achiev
inactiv
west
nile
viru
vaccinia
viru
addit
data
support
use
model
virus
predict
inactiv
similar
emerg
viral
pathogen
plasmaderiv
product
clot
factor
intraven
immunoglobulin
alpha
proteinas
inhibitor
pi
human
serum
albumin
routin
use
clinic
practic
safeti
product
respect
transmiss
infecti
virus
never
higher
high
margin
viral
safeti
attribut
number
measur
manufactur
implement
last
decad
measur
part
multifacet
strategi
pathogen
safeti
includ
donor
screen
donat
test
viru
inactiv
remov
measur
manufactur
strict
adher
good
manufactur
procedur
postus
surveil
product
howev
recent
outbreak
emerg
virus
west
nile
viru
wnv
sever
acut
respiratori
syndrom
sar
associ
coronaviru
monkeypox
indic
potenti
threat
blood
suppli
exist
result
reevalu
current
pathogen
safeti
strategi
plasma
product
although
donor
deferr
plasma
donat
screen
effect
provid
safeti
known
pathogen
presenc
new
emerg
viru
detect
exist
anticip
consequ
robust
viral
clearanc
procedur
within
manufactur
process
critic
capac
procedur
remov
inactiv
virus
valid
smallscal
studi
high
level
viru
spike
manufactur
intermedi
reduct
infecti
viru
measur
typic
number
experi
perform
use
differ
viru
could
potenti
present
plasma
potenti
contamin
hepat
c
viru
hcv
parvoviru
readili
cultur
vitro
virus
like
close
relat
viru
similar
physicochem
properti
easili
propag
laboratori
use
like
hcv
bovin
viral
diarrhoea
viru
bvdv
member
flavivirida
use
mani
year
model
hcv
virus
flavivirus
yellow
fever
viru
tickborn
enceph
viru
well
alphavirus
sindbi
viru
semliki
forest
viru
also
use
model
hcv
inactiv
remov
bvdv
hcv
model
virus
variou
manufactur
process
effect
repres
hcv
clearanc
evidenc
lack
hcv
transmiss
product
claim
signific
level
bvdv
clearanc
wnv
mosquitoborn
enceph
viru
epidem
unit
state
wnvinfect
individu
subclin
infect
short
defin
viraem
period
epidem
wnv
infect
preval
viraemia
within
popul
high
risk
viraem
blood
plasma
donor
also
high
fact
wnv
transmit
transplant
recipi
infect
organ
donor
recipi
whole
blood
platelet
infect
donor
result
implement
unit
state
food
drug
administr
fda
endors
wnv
screen
programm
whole
blood
programm
includ
donor
deferr
question
nucleic
acid
amplif
test
nat
fda
european
agenc
evalu
medicin
product
emea
concur
manufactur
plasma
product
variou
viralinactiv
measur
use
process
product
suffici
provid
high
degre
safeti
viru
live
vaccinia
viru
vv
vaccin
recent
use
part
unit
state
nation
smallpox
immun
program
interim
recommend
center
diseas
control
advis
immun
vaccin
individu
risk
monkeypox
infect
possibl
transmiss
vv
whole
blood
plasma
donat
recent
vaccin
individu
result
recommend
fda
defer
donor
recent
receiv
smallpox
vaccin
recent
evalu
inactiv
two
newli
emerg
potenti
contamin
threat
wnv
vv
vv
uniqu
envelop
viru
complex
lipid
membran
structur
although
studi
evalu
vv
inactiv
alway
includ
panel
virus
use
viru
clearanc
studi
plasmaderiv
product
wnv
member
flavivirida
close
relat
bvdv
use
mani
year
model
hcv
would
expect
wnv
inactiv
would
similar
bvdv
wnvinactiv
studi
could
verifi
valid
use
bvdv
model
virusinactiv
studi
virusinactiv
data
present
demonstr
current
virusinactiv
procedur
provid
inactiv
wnv
vv
support
use
virusinactiv
data
model
virus
manufactur
process
intermedi
antihaemophil
factor
ahf
intraven
immunoglobulin
ivigsd
produc
use
solventdeterg
process
ivigc
produc
use
capryl
chromatographi
process
intramuscular
immunoglobulin
igim
pi
albumin
obtain
bayer
healthcar
plasma
fraction
facil
clayton
nc
human
plasma
protein
solut
hpp
obtain
bayer
healthcar
recombin
factor
viii
manufactur
facil
berkeley
ca
hpp
use
compon
product
medium
human
albumin
protein
solut
pasteur
studi
aliquot
stabil
pi
hpp
albumin
albumin
heat
c
spike
vv
wnv
vv
bvdv
viru
spike
product
mix
well
incub
c
h
aliquot
remov
indic
time
place
ice
immedi
assay
infecti
viru
separ
unheat
virusspik
product
sampl
use
determin
initi
viru
concentr
pi
intermedi
ph
stabil
pasteur
citrat
sucros
hpp
albumin
aqueou
solut
ph
hpp
albumin
stabil
n
acetyldl
tryptophan
sodium
capryl
albumin
stabil
n
acetyldl
tryptophan
sodium
capryl
smallscal
pasteur
experi
perform
ml
volum
manufactur
albumin
pasteur
final
contain
volum
viru
experi
similar
product
prolastin
pasteur
experi
approxim
product
scale
hpp
pasteur
experi
product
scale
product
ahf
product
intermedi
treat
tri
n
butyl
phosphat
tnbp
polysorb
tween
h
c
studi
concentr
stock
solut
tnbp
tween
ad
aliquot
ahf
intermedi
solut
viru
ad
solut
vv
mixtur
incub
c
h
aliquot
remov
titrat
indic
timepoint
viru
ad
hank
balanc
salt
solut
hbss
v
v
untreat
control
smallscal
experi
conduct
volum
approxim
product
scale
product
ivigsd
imig
process
intermedi
incub
sodium
cholat
cholat
h
c
protein
concentr
adjust
ph
adjust
vv
wnvor
bvdvinactiv
studi
concentr
tnbp
cholat
stock
solut
ad
aliquot
process
intermedi
spike
vv
viru
mixtur
incub
c
h
aliquot
remov
indic
timepoint
quantif
infecti
viru
hbss
spike
v
v
viru
use
untreat
control
smallscal
experi
conduct
volum
approxim
product
scale
caprylateinactiv
experi
carri
describ
previous
briefli
capryl
ad
intermedi
specifi
final
concentr
throughout
addit
capryl
ph
process
intermedi
maintain
ad
either
acet
acid
sodium
hydroxid
solut
spike
vv
viru
phadjust
virusspik
solut
incub
c
min
aliquot
viru
titrat
remov
solut
indic
time
throughout
incub
smallscal
experi
conduct
volum
approxim
product
scale
although
capryl
use
step
product
concentr
capryl
evalu
studi
rang
intermedi
contain
residu
capryl
capryl
stock
solut
ad
increas
capryl
level
within
desir
rang
confirm
target
capryl
rang
reach
inactiv
experi
concentr
capryl
process
intermedi
follow
addit
measur
analyt
test
could
perform
virusspik
solut
mockspik
solut
contain
vv
viru
propag
medium
instead
viru
gener
manufactur
final
product
ph
incub
c
day
envelop
virusinactiv
step
studi
final
product
adjust
ph
spike
vv
wnv
incub
c
sampl
remov
day
infecti
wnv
quantifi
ph
normal
ph
rang
use
product
repres
worstcas
situat
volum
use
virusinactiv
experi
similar
final
contain
size
product
vv
wr
strain
propag
assay
apptec
laboratori
servic
camden
nj
wnv
except
use
lowph
incub
studi
also
propag
assay
apptec
laboratori
servic
infecti
wnv
vv
quantifi
make
endpoint
serial
log
dilut
test
sampl
posit
control
serumfre
medium
vv
assay
plaqu
assay
use
monkey
kidney
indic
cell
wnv
strain
assay
plaqu
assay
use
african
green
monkey
kidney
vero
cell
virus
aliquot
serial
dilut
sampl
plate
multipl
well
sixwel
plate
viru
titr
report
plaqueform
unit
pfu
per
ml
wnv
strain
use
lowph
incub
studi
propag
assay
vero
cell
obtain
american
type
cultur
collect
atcc
rockvil
md
sindbi
viru
strain
propag
assay
babi
hamster
kidney
cell
obtain
atcc
bvdv
strain
obtain
biolog
research
facil
faculti
ijamsvil
md
propag
madindarbi
bovin
kidney
mdbk
cell
assay
bovin
turbin
bt
cell
test
sampl
neutral
assay
inhous
virus
quantifi
tissu
cultur
infecti
dose
tcid
dilut
replic
aliquot
plate
well
microtitr
plate
cell
monolay
observ
microscop
presenc
viral
infect
indic
viral
cytopath
effect
cpe
well
score
posit
neg
result
convert
titr
log
median
tcid
ml
use
method
spearman
karber
duck
hepat
b
viru
dhbv
hepat
b
viru
hbv
surrog
obtain
hepadnaviru
test
inc
palo
alto
ca
consist
dhbvcontain
serum
obtain
congenit
infect
duckl
viru
assay
apptec
laboratori
servic
primari
duck
hepatocyt
sampl
serial
dilut
ml
dilut
assay
quadrupl
plate
ten
day
follow
inocul
monolay
fix
well
contain
infect
hepatocyt
identifi
use
fluoresc
microscopi
incub
murin
monoclon
antibodi
dhbv
surfac
antigen
wash
subsequ
incub
fluorescein
isothiocyan
fitc
conjug
sheep
antibodi
mous
immunoglobulin
g
result
convert
titr
use
method
spearman
karber
viru
assay
limit
detect
base
result
cytotox
viral
interfer
experi
evalu
whether
product
intermedi
toxic
indic
cell
interf
abil
viru
infect
cell
data
tabl
show
inactiv
wnv
vv
bvdv
pi
pasteur
c
protein
concentr
mgml
citrat
buffer
contain
citrat
sucros
stabil
heat
vv
reduc
log
within
h
h
undetect
wnv
bvdv
inactiv
lower
limit
detect
within
h
infecti
viru
undetect
h
c
total
log
log
log
wnv
vv
bvdv
respect
inactiv
wnv
vv
also
inactiv
pasteur
hpp
tabl
solut
contain
mgml
protein
stabil
sodium
capryl
acetyltryptophan
complet
inactiv
wnv
observ
min
heat
c
result
total
inactiv
log
approxim
four
log
vv
inactiv
within
min
within
h
pasteur
infecti
vv
detect
total
inactiv
log
vv
observ
albumin
spike
either
wnv
bvdv
pasteur
h
infecti
viru
inactiv
tabl
within
min
incub
albumin
wnv
near
lower
limit
detect
bvdv
could
detect
pasteur
albumin
inactiv
log
wnv
log
bvdv
similarli
pasteur
albumin
result
complet
inactiv
wnv
bvdv
within
min
total
log
wnv
log
bvdv
clear
within
h
incub
ahf
intermedi
either
tween
tween
infecti
wnv
could
detect
fig
product
oper
concentr
tween
result
log
inactiv
wnv
concentr
dilut
twofold
log
inactiv
also
observ
tabl
solut
ahf
spike
bvdv
incub
tween
tween
result
log
log
inactiv
respect
tabl
contrast
vv
resist
inactiv
condit
follow
h
incub
tween
log
inactiv
achiev
fig
tabl
treat
tri
nbutyl
phosphat
tnbp
tween
inactiv
infecti
wnv
tween
tween
b
vv
tween
determin
solut
intraven
immunoglobulin
produc
use
solventdeterg
process
ivigsd
inactiv
c
wnv
cholat
cholat
vv
cholat
determin
wnv
point
repres
mean
three
determin
vv
point
repres
singl
determin
dash
line
panel
b
repres
limit
detect
overal
reduct
factor
present
tabl
tabl
viru
inactiv
tri
nbutyl
phosphat
tnbp
tween
solut
antihaemophil
factor
ahf
tnbpcholat
intraven
immunoglobulin
produc
use
solventdeterg
process
ivigsd
inactiv
step
fig
b
fig
b
fig
c
e
fig
west
nile
viru
wnv
valu
repres
mean
three
determin
bovin
viral
diarrhoea
viru
bvdv
valu
repres
mean
two
three
determin
vaccinia
viru
vv
valu
result
singl
determin
solventdeterg
solut
incub
h
incub
wnv
ivigsd
process
intermedi
solut
contain
either
cholat
manufactur
condit
cholat
result
complet
inactiv
viru
within
min
fig
approxim
log
wnv
inactiv
tabl
similarli
cholat
cholat
log
log
bvdv
inactiv
respect
observ
tabl
unlik
observ
tnbptween
complet
rapid
inactiv
vv
achiev
treatment
ivigsd
tnbp
cholat
within
min
log
inactiv
achiev
h
infecti
viru
could
detect
fig
total
log
vv
inactiv
tabl
similarli
wnv
readili
inactiv
igim
process
intermedi
incub
either
tnbp
cholat
manufactur
condit
tnbp
cholat
fig
complet
inactiv
observ
within
min
incub
total
inactiv
log
log
achiev
cholat
cholat
respect
treatment
intermedi
solut
sodium
capryl
result
complet
inactiv
wnv
vv
within
min
mm
capryl
log
wnv
inactiv
fig
tabl
incub
mm
capryl
log
vv
inactiv
fig
tabl
capryl
previous
shown
provid
robust
effect
inactiv
human
immunodefici
viru
hiv
pseudorabi
viru
prv
bvdv
evalu
efficaci
innov
method
inactiv
envelop
viru
addit
model
hbv
hcv
use
inactiv
studi
tabl
data
demonstr
infecti
dhbv
hbv
surrog
could
detect
follow
incub
mm
capryl
within
min
dhbv
inactiv
complet
kinet
shown
anoth
model
hcv
sindbi
similarli
shown
rapidli
complet
inactiv
mm
capryl
inactiv
hiv
prv
bvdv
previous
shown
robust
respect
capryl
concentr
robust
inactiv
bvdv
respect
protein
concentr
ph
incub
temperatur
also
demonstr
investig
robust
capryl
inactiv
envelop
virus
seri
studi
perform
evalu
robust
sindbi
viru
inactiv
respect
capryl
concentr
protein
concentr
ph
incub
temperatur
data
shown
tabl
demonstr
within
rang
investig
oper
paramet
influenc
sindbi
inactiv
capryl
condit
complet
inactiv
sindbi
observ
within
min
kinet
shown
incub
final
product
ph
result
effect
inactiv
wnv
fig
within
fig
kinet
west
nile
viru
wnv
inactiv
treatment
intramuscular
immunoglobulin
imig
tri
nbutyl
phosphat
tnbp
cholat
cholat
point
repres
mean
three
determin
total
inactiv
log
log
wnv
achiev
cholat
cholat
respect
tabl
day
incub
ph
wnv
near
lower
limit
detect
next
timepoint
day
complet
inactiv
achiev
total
log
inactiv
observ
effect
inactiv
wnv
bvdv
vv
pasteur
demonstr
varieti
protein
solut
even
presenc
stabil
although
albumin
hpp
pi
util
differ
excipi
stabil
eg
sucros
citrat
tryptophan
differ
protein
concentr
complet
inactiv
virus
achiev
demonstr
technolog
provid
robust
inactiv
envelop
virus
complet
inactiv
wnv
bvdv
vv
observ
albumin
similar
inactiv
virus
would
expect
intermedi
concentr
wnv
vv
previous
shown
suscept
inactiv
heat
complet
inactiv
vv
observ
pasteur
solut
immunoglobulin
recent
report
demonstr
inactiv
wnv
pasteur
albumin
number
studi
includ
one
demonstr
inactiv
pasteur
virus
close
relat
wnv
bvdv
tick
born
enceph
viru
yellow
fever
viru
sindbi
viru
data
report
demonstr
fig
fig
similar
inactiv
wnv
bvdv
pasteur
pi
albumin
support
predict
valu
inactiv
inform
model
virus
vv
antigen
similar
enough
variola
smallpox
monkeypox
virus
use
vaccin
suscept
pasteur
monkeypox
viru
variola
viru
probabl
similar
vv
solventdeterg
treatment
wide
use
inactiv
lipidenvelop
virus
treatment
ahf
intermedi
tnbptween
concentr
use
manufactur
process
provid
rapid
complet
inactiv
wnv
result
similar
relat
viru
bvdv
support
valid
viru
model
wnv
vv
howev
resist
inactiv
tnbp
tween
productionoper
concentr
tnbp
tween
achiev
complet
inactiv
vv
although
viru
titr
reduc
log
resist
vv
solventdeterg
previous
observ
vv
unlik
envelop
virus
present
two
infecti
form
membran
one
doubl
membran
complex
structur
contrast
tnbptween
studi
tnbpcholat
provid
effect
inactiv
wnv
vv
treatment
human
placent
tissu
cholat
result
substanti
incomplet
vv
inactiv
current
studi
tnbpcholat
solut
ivig
rather
tissu
incub
complet
inactiv
viru
achiev
cholat
may
abl
solubil
vv
membran
effici
deterg
thu
tnbpcholat
data
provid
evid
abil
method
effect
inactiv
envelop
virus
wide
varieti
characterist
also
suggest
emerg
envelop
viru
characterist
similar
virus
tnbpcholat
data
exist
also
suscept
inactiv
method
wnv
effect
inactiv
lowph
incub
step
process
even
incub
perform
ph
upper
ph
limit
manufactur
rang
ph
suscept
viru
lowphmedi
inactiv
previous
demonstr
current
data
confirm
incub
product
condit
low
ph
similarli
achiev
inactiv
viru
like
manufactur
step
perform
low
ph
would
effect
inactiv
wnv
vaccinia
also
shown
suscept
inactiv
low
ph
capryl
treatment
provid
rapid
complet
inactiv
wide
panel
envelop
virus
evalu
date
envelop
virus
evalu
repres
wide
varieti
physicochem
characterist
inactiv
limit
detect
within
minut
incub
capryl
capryl
inactiv
vv
similar
envelop
virus
demonstr
altern
solventdeterg
treatment
inactiv
resist
envelop
virus
data
also
suggest
emerg
envelop
viru
complex
lipid
membran
may
similarli
suscept
mean
inactiv
data
present
support
robust
inactiv
envelop
virus
capryl
number
envelop
virus
repres
varieti
viru
famili
shown
complet
inactiv
within
minut
incub
capryl
addit
data
obtain
use
sindbi
viru
demonstr
manufactur
process
variat
capryl
concentr
protein
concentr
ph
incub
temperatur
would
alter
overal
inactiv
inactiv
kinet
hcv
surrog
data
also
demonstr
valid
use
model
virus
inactiv
studi
inactiv
wnv
pasteur
solventdeterg
treatment
capryl
treatment
similar
observ
bvdv
studi
use
surrog
virus
virus
readili
cultur
vitro
wide
use
strategi
advoc
regulatori
agenc
bvdv
use
model
hcv
mani
year
abil
predict
inactiv
hcv
verifi
lack
transmiss
pathogen
blood
product
subject
inactiv
measur
achiev
signific
level
bvdv
inactiv
wnv
data
present
support
use
model
virus
wnv
inactiv
mirror
bvdv
appear
novel
viral
pathogen
place
safeti
plasmaderiv
product
jeopardi
long
data
virus
similar
physicochem
characterist
support
effect
inactiv
manufactur
data
studi
wide
panel
model
virus
repres
rang
physicochem
properti
provid
basi
determin
whether
emerg
pathogen
like
present
threat
biolog
product
although
data
model
virus
predict
safeti
plasmaderiv
product
respect
transmiss
wnv
vv
potenti
viral
contamin
similar
properti
result
current
studi
provid
definit
confirm
consist
conclus
other
furthermor
data
justifi
model
viru
approach
assess
viral
safeti
product
